Championing novel science
Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Szukaj
Our Innovation Strategy
Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Bigger role in ensuring food security
As the world population is projected to reach 9.8 billion in 2050, animal health becomes fundamental to ensure both animal well-being and global protein supply.
View from Both Sides of the Table
Stawiamy na zarządzanie aliansami
Equestrian sports technology
Learn about new trends in equine health and get insights into the human-horse relationship!
Guardians for health
sA global initiative to reduce mortality, cardiovascular and kidney complications in type 2 diabetes through adherence to clinical guideline.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Trust Through Transparency
Trust Through Transparency
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Collaboration Driving Innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
1990-2022: Wartość dzięki innowacjom
The Boehringer Ingelheim history from 1990 to 2022, with milestones
Być niezależnym
Kultura korporacyjna Boehringer Ingelheim opiera się na wartościach, które są stosowane od momentu założenia firmy w 1885 roku.
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Historia (1885-1948): Nowatorskie początki
Historia Boehringer Ingelheim od rozpoczęcia działalności w 1885 roku do 1948 roku, z kamieniami milowymi i ważnymi produktami